Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070305 | 1.00 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL6802898 | 0.83 | HCAR2 (0.47) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL2651775 | 0.77 | CASP1 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL7071569 | 0.77 | NPSR1 (0.42) | HCAR2ALDH1A1EGLN1MAPTMEN1 | |
| SCHEMBL7071574 | 0.77 | NPSR1 (0.42) | HCAR2ALDH1A1EGLN1MAPTMEN1 | |
| SCHEMBL2651778 | 0.77 | CASP1 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1TET2 | |
| SCHEMBL7838518 | 0.76 | — | — | |
| SCHEMBL7838519 | 0.76 | — | — | |
| SCHEMBL7031398 | 0.76 | — | — | |
| SCHEMBL12651643 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | claimed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | claimed |
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | HCAR2 672/4885KEAP1 901/4885NFE2L2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.